A carregar...
The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors
Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure and the development of acquired resistance is the rule rather than the exception. CDK4/6 and PIM1 kinases are potential new therapeutic targets in RCC. Abemaciclib is a potent CDK4/6 and PIM1 kinase inhi...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5707010/ https://ncbi.nlm.nih.gov/pubmed/29221116 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19618 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|